Compare AGNCM & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
AGNC Investment Corp. Depositary Shares rep 6.875% Series D Fixed-to-Floating Cumulative Redeemable Preferred Stock
Current Price
Current Price
| Metric | AGNCM | IRWD |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | 54 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 663.6M |
| IPO Year | N/A | 2009 |
| Metric | AGNCM | IRWD |
|---|---|---|
| Price | $25.00 | $3.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 9.3K | ★ 2.6M |
| Earning Date | 01-26-2026 | 05-11-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $13.57 | $57.95 |
| Revenue Next Year | $63.17 | $4.39 |
| P/E Ratio | $17.72 | ★ $15.00 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $23.63 | $0.56 |
| 52 Week High | $25.34 | $5.78 |
| Indicator | AGNCM | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 41.21 |
| Support Level | $24.98 | $3.07 |
| Resistance Level | $25.04 | $3.92 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 82.86 | 16.07 |
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage, or real estate markets.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.